• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

New Pediatric Labeling Information Database - Detail

  • Print
  • Share
  • E-mail
Pediatric Labeling Date:  06/14/2007
Trade Name:  Lexiva Oral Suspension
Generic Name or Proper Name (*):  fosamprenavir
Indications Studied:  Treatment of HIV infection in patients 2-18 years of age
Label Changes Summary:  * Effectiveness and safety were established in two clinical studies of pediatric patients 2-18 years of age * Adverse event profile is similar to that of adults with the exception of vomiting, which, regardless of causality, occurred more frequently among pediatric patients * Dosing information provided * Studies waived in children 0-1 month of age and deferred in children 1 month - 2 years of age * New dosage form
Product Labeling:  Labeling  Opens a new window
Sponsor:  GlaxoSmithKline
Therapeutic Category:  Antiviral